Last time we talked about the meanings of the letters in stock names, and mentioned a bit. $BIOCYTOGEN-B (02315.HK)$On the way here, not sure if we can break out of the independent market trend, sweeping away the long-standing downturn of B shares, after all, B shares have been a topic of terror for a long time.
As the saying goes, 'mention Cao Cao and Cao Cao arrives,' the efficiency of Bao Ai Sai Tu is still very high, from the hearing to the IPO, all in one go, really overwhelming. While at it, let's say a few more words here: $HONGJIU FRUIT (06689.HK)$， $CALB (03931.HK)$， $GIANT BIOGENE (02367.HK)$For this IPO, let's move quickly, urge to submit the documents, urge the progress of the Hong Kong Stock Exchange.？
As usual, let's start with a set of fundamental valuation.
01/Fundamentals
According to the prospectus, Baioo Scientific, as a biotechnology company, primarily operates in drug development and preclinical research services, with drug development focused on tumors, autoimmune diseases, and antibody development; preclinical research includes gene editing, preclinical drug pharmacology evaluation, and model animal sales.
According to research data from 2011 to 2020, the success rate of drug development from clinical Phase I to market approval is less than 10%, with Phase II clinical trials being the bottleneck of the entire process. After looking at the drug development pipeline of Bio-Thera Solutions, the lineup is very rich...